Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Cell-Mediated Immunity and Cancer Vaccines
share announcement

Cell-Mediated Immunity and Cancer Vaccines

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 17862

Special Issue Editors

Prof. Dr. Alexandr V. Bazhin

E-Mail Website
Guest Editor
Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, Marchioninistraße 15, 81377 Munich, Germany
Interests: cancer immunology and biochemistry; reactive oxygen species; transplant immunology; cancer immunotherapy
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Andrey Zamyatnin

E-Mail Website
Guest Editor
1. Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia
2. Scientific Center for Translation Medicine, Sirius University of Science and Technology, 354340 Sochi, Russia
3. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia
4. Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7X, UK
Interests: programmed cell death; protein processing; intracellular communications; virus-cell interactions; regulation of gene expression; RNAi; oxidative stress; aging; neurodegeneration; ophthalmology; cancer; regenerative medicine; personalized medicine; molecular markers; biotechnology; drug design; novel drug candidates; plant biology; virology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Current advances in cancer treatment are merely based on the recent discoveries of molecular mechanisms of tumor maintenance. Malignant cells being transformed become “visible” for immune system, i.e., they will be immunogenic. This is a rationale for the development of cancer vaccines. Taking into account the fact that anticancer vaccines are relatively safe and show no toxic effects compared with traditional chemo- and radiotherapy, anticancer vaccination could be a very attractive therapeutic strategy in cancer immunotherapy. However, there are several obstacles to introducing the anticancer vaccination into medical practice. The problems to achieve a good therapeutic effect are complex and include, among other things, the immunosuppressive tumor microenvironment, activation of immunosuppression by vaccination itself, immunosuppressive check-point molecules, tumor antigen and epitope selection, vaccine production methods, etc. Therefore, the cell-mediated immunity is recognized as a crucial key player for the development of an anticancer vaccine. The main aim of the Special Issue is to collect novel findings from scientists involved in basic research as well as in translational studies in the field of anticancer vaccine.

Prof. Dr. Alexandr V. Bazhin
Prof. Dr. Andrey A. Zamyatnin Jr.
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer vaccines
  • cell-mediated immunity
  • cancer immunotherapy
  • combined immunotherapy
  • dendritic cells
  • immunosuppressive cells
  • check-point molecules
  • tumor antigens
  • antigen epitops

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

14 pages, 297 KiB  
Review
The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
by Elena V. Abakushina, Liubov I. Popova, Andrey A. Zamyatnin, Jr., Jens Werner, Nikolay V. Mikhailovsky and Alexandr V. Bazhin
Vaccines 2021, 9(11), 1363; https://doi.org/10.3390/vaccines9111363 - 19 Nov 2021
Cited by 23 | Viewed by 5476
Abstract
In the last decade, an impressive advance was achieved in adoptive cell therapy (ACT), which has improved therapeutic potential and significant value in promising cancer treatment for patients. The ACT is based on the cell transfer of dendritic cells (DCs) and/or immune effector [...] Read more.
In the last decade, an impressive advance was achieved in adoptive cell therapy (ACT), which has improved therapeutic potential and significant value in promising cancer treatment for patients. The ACT is based on the cell transfer of dendritic cells (DCs) and/or immune effector cells. DCs are often used as vaccine carriers or antigen-presenting cells (APCs) to prime naive T cells ex vivo or in vivo. Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are used as major tool effector cells for ACT. Despite the fact that NK cell immunotherapy is highly effective and promising against many cancer types, there are still some limitations, including insignificant infiltration, adverse conditions of the microenvironment, the immunosuppressive cellular populations, and the low cytotoxic activity in solid tumors. To overcome these difficulties, novel methods of NK cell isolation, expansion, and stimulation of cytotoxic activity should be designed. In this review, we discuss the basic characteristics of DC vaccines and NK cells as potential adoptive cell preparations in cancer therapy. Full article
(This article belongs to the Special Issue Cell-Mediated Immunity and Cancer Vaccines)
33 pages, 1071 KiB  
Review
mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients
by Maryam Bidram, Yue Zhao, Natalia G. Shebardina, Alexey V. Baldin, Alexandr V. Bazhin, Mohamad Reza Ganjalikhany, Andrey A. Zamyatnin, Jr. and Mazdak Ganjalikhani-hakemi
Vaccines 2021, 9(10), 1060; https://doi.org/10.3390/vaccines9101060 - 23 Sep 2021
Cited by 47 | Viewed by 11506
Abstract
Malignant melanoma is one of the most aggressive forms of cancer and the leading cause of death from skin tumors. Given the increased incidence of melanoma diagnoses in recent years, it is essential to develop effective treatments to control this disease. In this [...] Read more.
Malignant melanoma is one of the most aggressive forms of cancer and the leading cause of death from skin tumors. Given the increased incidence of melanoma diagnoses in recent years, it is essential to develop effective treatments to control this disease. In this regard, the use of cancer vaccines to enhance cell-mediated immunity is considered to be one of the most modern immunotherapy options for cancer treatment. The most recent cancer vaccine options are mRNA vaccines, with a focus on their usage as modern treatments. Advantages of mRNA cancer vaccines include their rapid production and low manufacturing costs. mRNA-based vaccines are also able to induce both humoral and cellular immune responses. In addition to the many advantages of mRNA vaccines for the treatment of cancer, their use is associated with a number of challenges. For this reason, before mRNA vaccines can be used for the treatment of cancer, comprehensive information about them is required and a large number of trials need to be conducted. Here, we reviewed the general features of mRNA vaccines, including their basis, stabilization, and delivery methods. We also covered clinical trials involving the use of mRNA vaccines in melanoma cancer and the challenges involved with this type of treatment. This review also emphasized the combination of treatment with mRNA vaccines with the use of immune-checkpoint blockers to enhance cell-mediated immunity. Full article
(This article belongs to the Special Issue Cell-Mediated Immunity and Cancer Vaccines)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop